Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine (Q44323798)

2 December 2017

title

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine (English)

1 reference

2 December 2017

1 reference

1 reference

2 December 2017

Alberto Garaventa

0 references

Claudio Gambini

1 reference

2 December 2017

Giampiero Villavecchia

1 reference

2 December 2017

Andrea Di Cataldo

1 reference

2 December 2017

Luigi Bertolazzi

1 reference

2 December 2017

Maria Rosa Pizzitola

1 reference

2 December 2017

Bruno De Bernardi

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

2 December 2017

1 reference

2 December 2017

1 reference

2 December 2017

1 reference

2 December 2017

page(s)

1332-1338

1 reference

Molecular biology of neuroblastoma

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Role of 131I-metaiodobenzylguanidine in the treatment of neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Pretreatment with [131I] metaiodobenzylguanidine and surgical resection of advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Angiomatoid (malignant) fibrous histiocytoma as a second tumour in a child with neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Second cancers following pediatric Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Meta-iodobenzylguanidine uptake in platelets, megakaryoblastic leukaemia cell lines MKPL-1 and CHRF-288-11 and erythroleukaemic cell line HEL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

I-131 localization in acute megakaryocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Two secondary leukemias among 15 children given oral etoposide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Papillary thyroid carcinoma: demographics, treatment, and outcome in eleven pediatric patients treated at a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Osteosarcoma as a second malignancy after treatment for neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Metachronous renal cell carcinoma in a child cured of neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Thyroid carcinomas after irradiation for a first cancer during childhood

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Rat model of the human “Triton” tumor: direct genetic evidence for the myogenic differentiation capacity of schwannoma cells using the mutant neu gene as a cell lineage marker

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11167

7 January 2021

Identifiers

DOI

10.1002/CNCR.11167

1 reference

2 December 2017

1 reference